Hormonization of female transgenders: analysis of adverse events

Authors

  • Altino Caetano da Silva Neto Universidade Estadual de Feira de Santana Departamento de Saúde Endereço: Av. Transnordestina, s/n - Feira de Santana, Novo Horizonte - BA, 44036-900 http://orcid.org/0000-0002-9249-4751
  • Marilia Pinto Federico Universidade Estadual de Feira de Santana Departamento de Saúde Endereço: Av. Transnordestina, s/n - Feira de Santana, Novo Horizonte - BA, 44036-900 http://orcid.org/0000-0001-6526-4945

DOI:

https://doi.org/10.14450/2318-9312.v34.e3.a2022.pp202-213

Keywords:

transgender person, transsexual, sex hormones, adverse events

Abstract

The commercialization of hormones as contraceptives was contemporary with the transgender phenomenon. Currently, estrogen and anti-androgen hormones are essential for the female transgender population as a tool for the transsexualization process guaranteed by law. This study aimed to investigate
adverse events related to the use of hormones by the transgender female population for hormone purposes. Therefore, an integrative literature review was carried out, seeking complete articles available in the Virtual Health Library database published in English and Portuguese between 2011 and 2021, using the descriptors transgender woman, transsexual woman, trans people, transgender, female transsexual, and hormone. The most cited drugs were the hormones estradiol acetate, estradiol valerate, cyproterone, and the anti-androgens, spironolactone, and fi nasteride. The most frequent adverse events were the development of thrombi and mood changes, followed by changes in hematopoiesis parameters, decreased fertility, and changes in prolactin levels and bone density. Multidisciplinary health teams, including pharmacists, must
be prepared to serve the trans female population, providing guidance on the correct use of hormones and monitoring treatment, contributing to better care, and preventing or reducing adverse events. 

Author Biographies

Altino Caetano da Silva Neto, Universidade Estadual de Feira de Santana Departamento de Saúde Endereço: Av. Transnordestina, s/n - Feira de Santana, Novo Horizonte - BA, 44036-900

Farmacêutico pela Universidade Estadual de Feira de Santana (UEFS). Pesquisador colaborador da UEFS e foi bolsista de Iniciação Científica (CNPq) no Laboratório de Modelagem Molecular da UEFS.

Marilia Pinto Federico, Universidade Estadual de Feira de Santana Departamento de Saúde Endereço: Av. Transnordestina, s/n - Feira de Santana, Novo Horizonte - BA, 44036-900

Doutorado em Ciências (Infectologia) pela Universidade Federal de São Paulo (UNIFESP). Mestrado em Saúde Coletiva pela Universidade Estadual de Feira de Santana (UEFS). Especialização em Farmácia Hospitalar pela Universidade Federal do Rio Grande do Norte (UFRN). Graduação em Farmácia pela Universidade Federal da Bahia (UFBA). Atuação em Farmácia Comunitária, Farmácia Magistral, Hospital Geral, Hospital Oncológico, Distribuidora de Medicamentos, Distribuidora de Material Médico-Hospitalar e docência. Atualmente é Professora Adjunta da Universidade Estadual de Feira de Santana. Tem experiência na área de Farmácia, com ênfase em Farmácia Hospitalar, atuando principalmente nos seguintes temas: farmacoepidemiologia, resistência bacteriana, antimicrobiano, farmácia hospitalar, farmácia clínica, gestão de serviços farmacêuticos.

Downloads

Published

2022-09-30

How to Cite

Silva Neto, A. C. da, & Federico, M. P. (2022). Hormonization of female transgenders: analysis of adverse events. Infarma - Pharmaceutical Sciences, 34(3), 202–213. https://doi.org/10.14450/2318-9312.v34.e3.a2022.pp202-213

Issue

Vol. 34 No. 3 (2022)

Section

Review Article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).